Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
出版年份 2022 全文链接
标题
Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
作者
关键词
-
出版物
ONCOGENE
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-01-11
DOI
10.1038/s41388-021-02170-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- β2-adrenergic signals downregulate the innate immune response and reduce host resistance to viral infection
- (2020) Elisabeth Wieduwild et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Prognostic Implications of Tumor Infiltrating Lymphocytes in Colorectal Cancer: A Systematic Review and Meta-Analysis
- (2020) Gregory E. Idos et al. Scientific Reports
- Tumor microenvironment complexity and therapeutic implications at a glance
- (2020) Roghayyeh Baghban et al. Cell Communication and Signaling
- Lipin-1 Contributes to IL-4 Mediated Macrophage Polarization
- (2020) Sunitha Chandran et al. Frontiers in Immunology
- Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors
- (2020) Aohan Hou et al. Frontiers in Immunology
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade
- (2020) Elisa Peranzoni et al. Frontiers in Immunology
- The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy
- (2020) Christiana M. Neophytou et al. Frontiers in Oncology
- Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
- (2020) Rilan Bai et al. Biomarker Research
- Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression
- (2019) Atsunori Kamiya et al. NATURE NEUROSCIENCE
- Blockade of β-Adrenergic Receptors Improves CD8+ T-cell Priming and Cancer Vaccine Efficacy
- (2019) Clara Daher et al. Cancer Immunology Research
- Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy
- (2019) Yuting Liu et al. CLINICAL CANCER RESEARCH
- β2 adrenergic receptor–mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells
- (2019) Hemn Mohammadpour et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
- (2018) Sandra P D'Angelo et al. LANCET ONCOLOGY
- Neuroendocrine Control of Macrophage Development and Function
- (2018) Arnon Dias Jurberg et al. Frontiers in Immunology
- A review of soft-tissue sarcomas: translation of biological advances into treatment measures
- (2018) Ngoc T Hoang et al. Cancer Management and Research
- The β2-adrenergic receptor controls inflammation by driving rapid IL-10 secretion
- (2018) Didem Ağaç et al. BRAIN BEHAVIOR AND IMMUNITY
- β-Adrenergic signaling blocks murine CD8+ T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress
- (2018) Guanxi Qiao et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
- (2018) Robin Maximilian Awad et al. Frontiers in Immunology
- TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
- (2018) David P. Enot et al. OncoImmunology
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model
- (2017) Cameron S. Field et al. OncoImmunology
- Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice
- (2017) Kathleen M. Kokolus et al. OncoImmunology
- QuPath: Open source software for digital pathology image analysis
- (2017) Peter Bankhead et al. Scientific Reports
- Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution
- (2016) Line Pedersen et al. Cell Metabolism
- β-Blocker use and mortality in cancer patients
- (2016) Shanliang Zhong et al. EUROPEAN JOURNAL OF CANCER PREVENTION
- Propranolol Attenuates Surgical Stress–Induced Elevation of the Regulatory T Cell Response in Patients Undergoing Radical Mastectomy
- (2016) Lei Zhou et al. JOURNAL OF IMMUNOLOGY
- Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study
- (2016) Eddy Pasquier et al. EBioMedicine
- Efficacy and Safety of High-Dose Propranolol for the Management of Infant Supraventricular Tachyarrhythmias
- (2015) Andrea L. Barton et al. JOURNAL OF PEDIATRICS
- Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment
- (2015) Laura Brohée et al. Oncotarget
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) ANNALS OF ONCOLOGY
- A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response
- (2014) Jason W.-L. Eng et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer
- (2013) Robert Wesolowski et al. Journal for ImmunoTherapy of Cancer
- Beta Blockers and Breast Cancer Mortality: A Population- Based Study
- (2011) Thomas I. Barron et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started